November 21, 2016
An analysis from Visante quantifying how PBMs generate $6 in savings for each $1 spent on their services. Major Findings...
PBMs build networks of pharmacies to provide consumers convenient access to prescriptions at discounted rates. PBMs also monitor prescription safety across all of the network pharmacies, alerting pharmacists to potential drug interactions, even if a consumer uses multiple pharmacies.
Network pharmacies compete on service, convenience, and quality to attract consumers within a particular plan. It is important for pharmacies to compete in order to be included in these pharmacy networks. This competition helps keep the rising costs of prescription drugs down.
October 13, 2016
Executive Summary This study examines whether the full range of pharmacy benefit management (PBM) tools are being allowed and used...
January 25, 2013
Over the past twenty years, pharmacy networks have generated significant savings. Today, there is even greater potential savings available through...
February 08, 2017
(Washington, D.C.) — As part of its DrugBenefitSolutions.com campaign, the Pharmaceutical Care Management Association (PCMA) today released a new video,...
June 08, 2016
(Washington, D.C.)— New York state legislation (S.2530 and A.6194) that creates a special exemption for drugstores from certain safety...
February 09, 2015
(Washington, D.C.)— “Any Willing Pharmacy” legislation (H.R. 793) in Medicare Part D, backed by the drugstore lobby, would undermine...
Specialty Drug Trends
Complex, innovative, and high-priced specialty drugs are entering the United States health care market at a rapid rate.
What is a specialty pharmacy network?
To maximize the patient benefit of drug treatments, preferred specialty pharmacy networks are used to deliver high-quality, accessible pharmacy services.
What is a PBM?
These drugs are best defined by the full range of each product's attributes, rather than solely by cost and route of administration.
What tools do PBMs use?
The total costs and utilization of specialty drugs will have a substantial impact on overall health care costs during the next decade.